ImmuQuad

ImmuQuad Biotech is a precision medicine company focused on the analysis of the human immune system through immune repertoire sequencing. Utilizing next-generation sequencing (NGS) and proprietary bioinformatics, the company provides high-sensitivity monitoring for minimal residual disease (MRD) in hematological cancers. Their technology platform profiles T-cell and B-cell receptors to assist in disease diagnosis, treatment monitoring, and drug development. ImmuQuad serves clinical laboratories, pharmaceutical companies, and research institutions with both diagnostic services and standardized kits. The company's flagship Seq-MRD product offers a non-invasive and highly accurate method for tracking cancer recurrence. By integrating immunology with big data, ImmuQuad aims to advance personalized healthcare in oncology and infectious diseases.